Meiragtx Holdings plc CEO Alexandria Forbes told BioWorld that the "very strong financial position" conferred by her firm's deal with New Brunswick, N.J.-based Johnson & Johnson arm Janssen Pharmaceuticals Inc. means that more money can go to the Parkinson's disease (PD) program. "We haven't given guidance about how long our cash is going to last," she said, but the London-based firm now has "multiple years" worth of resources.